Coronavirus COVID-19 Vaccine: A Scottish Scientist Dr Kate Broderick, has been working tirelessly with her team at Inovio (NASDAQ: INO), a pharmaceutical giant in San Diego, California, to develop a vaccine in just six months.
Dr Broderick said after the initial doses are made available the plan is to ramp-up production and get 50 to 100 million jabs released worldwide during 2021.
Broderick who is 42, studied at Glasgow University. she then went on to have her post-doctoral research at the University of California. She confirmed the additional $5 million donation by Bill and Melinda Gates Foundation to aid the development of the drugs.
Dr Broderick said:
“Not in my worst nightmares did I think it was going to get as bad as this.”
The team at Inovio are already three months ahead of schedule, having carried out successful tests on animals including rabbits, guinea pigs and primates.
Dr Broderick said:
“We’ll have a million doses and even though that sounds a lot, it’s really not that many when you spread it out over everybody who wants it – so that’s a start.
Then over the next six months to a year following that, we’d really scale up the manufacture so we had 50 to 100 million doses.
The most affected and people who would be most impacted – so it would primarily go to first responders, medical personnel and then also potentially people with other health conditions.
It’s hard to work out a costing structure [for the vaccine] until we know where we are in terms of epidemiology.”
Dr Broderick spoke of the concept of ‘herd immunity’ , something the UK Government had received a lot of criticism over with a large number of medical experts believing this was the course of action Boris Johnson was pursuing.
In reaction to that, she said:
“Herd immunity is a really important part of this process but we’re not going to get herd immunity until we have a vaccine.
So herd immunity is important but we’re nowhere close to having anything like that at the moment.
There’s a critical mass of the population who are protected and this percentage differs depending on the virus to be considered a herd immunity.
The vaccine would provide immunity and the others who aren’t immune would be somehow protected because there would be less cases of the coronavirus in society.”
Dr Broderick who has previously helped create successful vaccines for ebola, zika, lassa fever and Mers (Middle East Respiratory Syndrome) moved from Glasgow to California over 20 years ago.
“It’s possible that it [coronavirus] will go away over the next few months but it could come back and again it comes down to the fact that we’ve just no idea what’s going to happen to this virus.
A virus can mutate, it can change – it could just disappear and we’ll never, ever see it again.
That’s a possibility but I wouldn’t rely on any of those things as we’ve just no idea.
I knew it was going to be bad – every school here in San Diego is shut, the shops are empty and there’s no food on any of the shelves – it’s just crazy.
I’m sure nobody has experienced anything like this in their whole lives and unlikely never will again.
Some people are being told to work from home but it’s not like I can do that – so it’s really difficult”.
Lawsuit against Inovio
A recent complaint against Inovio (NASDAQ: INO) alleges that during the Class Period, Defendants capitalized on widespread COVID-19 fears by falsely claiming that Inovio Pharmaceuticals, Inc. had developed a vaccine for COVID-19.
The suit alleges that on February 14, 2020, Inovio CEO J. Joseph Kim stated that Inovio had developed a COVID-19 vaccine.
After March 2, 2020 meeting with President Trump to discuss the Coronavirus (COVID-19) outbreak, Kim again claimed Inovio had developed a vaccine.
The market allegedly responded favorably to Kim’s statement and Inovio’s stock price more than quadrupled.
The company’s shares went from $4.28 per share on February 28, 2020, to an intra-day high of $19.36 on March 9, 2020.
The lawsuit alleges that Inovio had not developed a COVID-19 vaccine.
The lawsuit states that on March 9, 2020, before trading commenced, Citron Research exposed Defendants’ misstatements, calling for an SEC investigation into the Company’s claim.
In response, Inovio’s stock price plummeted from its March 9 opening price of $18.72 per share to close at $9.83.
The following day, March 10, 2020, Inovio’s stock price fell from its $9.30 per share opening price to close at $5.70 per share.
© 2020, Our9Ja Trending News. All rights reserved. On republishing this post you must provide link to original post